Mounjaro (Tirzepatide)
- Drug Name: Mounjaro
- Generic Name: Tirzepatide
- Dosage Forms and Strengths:Injection: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg
- Manufactured by: Eli Lilly and Company
- Has not been studied in patients with a history of pancreatitis.
- It is not indicated for use in patients with type 1 diabetes mellitus.
- The recommended starting dosage is 2.5 mg, injected subcutaneously once weekly.
- After 4 weeks, increase to 5 mg injected subcutaneously once weekly.
- If additional glycemic control is needed, increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose.
- The maximum dosage is 15 mg subcutaneously once weekly.
- Administer once weekly at any time of day, with or without meals.
- Inject subcutaneously in the abdomen, thigh, or upper arm.
- Rotate injection sites with each dose.
- Pancreatitis: This has been reported in clinical trials. Discontinue promptly if pancreatitis is suspected.
- Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin: Concomitant use with an insulin secretagogue or insulin may increase the risk of hypoglycemia, including severe hypoglycemia. Reducing the dose of insulin secretagogue or insulin may be necessary.
- Hypersensitivity Reactions: Hypersensitivity reactions have been reported. Discontinue MOUNJARO if suspected.
- Acute Kidney Injury: Monitor renal function in patients with renal impairment reporting severe adverse gastrointestinal reactions.
- Severe Gastrointestinal Disease: Use may be associated with gastrointestinal adverse reactions, sometimes painful. Has not been studied in patients with severe gastrointestinal disease and is not recommended in these patients.
- Diabetic Retinopathy Complications in Patients with a History of Diabetic Retinopathy: Has not been studied in patients with non-proliferative diabetic retinopathy requiring acute therapy, proliferative diabetic retinopathy, or diabetic macular edema. Monitor patients with a history of diabetic retinopathy for progression.
- Acute Gallbladder Disease: Has occurred in clinical trials. If cholelithiasis is suspected, gallbladder studies and clinical follow-up are indicated.
If you are considering the import of Mounjaro (Tirzepatide) to India, please be aware that Mounjaro can be imported by patients or government hospitals solely in the name of the patients. The following documentation is essential for the successful import of this medication:
Required Documentation for Import:
- A valid prescription from a qualified medical practitioner.
- Diagnostic reports of the patient.
- Government-issued identification proof for the patient, as recognized by the Government of India.
Order Confirmation Process:
The order for Mounjaro will be confirmed upon the receipt of the following documents:
- A valid prescription from a qualified doctor.
- An import permit, if applicable.
Availability of Mounjaro in India:
Mounjaro (Tirzepatide) is classified as a prescription pharmaceutical drug. Consequently, it legally requires a medical prescription to be dispensed. Indian Pharma Network (IPN) specializes in facilitating the import of cancer medicines through named patient supply (NPS), ensuring transparency and authenticity by sourcing from reputable suppliers in the USA, Canada, Europe, and Australia.
Mounjaro (Tirzepatide) can be made accessible to patients, doctors, and hospitals in various cities across India, including but not limited to Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune. To confirm an order, a valid prescription from a doctor and an import permit will be required.
IPN (Indian Pharma Network) is dedicated to facilitating the supply of Mounjaro (prescription medicines) to locations within India and worldwide while adhering to relevant legal requirements.
Our commitment lies in assuring quality and timely delivery to meet the healthcare needs of patients and medical professionals across the globe.
Indian Pharma Network is proficient in sourcing Mounjaro (Tirzepatide) worldwide and ensuring efficient patient delivery. We provide worldwide access to the best available treatments and expedited prescription dispensing and delivery, with all prescriptions being dispensed and scrutinized by registered pharmacists before dispatching them to the patient’s address, exclusively from New Delhi, India.
Is tirzepatide FDA-approved yet?
Tirzepatide is a novel medication that is FDA-approved for the treatment of type 2 diabetes mellitus.
Is tripeptide marketed as Mounjaro?
Tirzepatide, marketed as Mounjaro, was approved in 2022 to treat diabetes but is also prescribed off-label for weight loss.
Is Mounjaro used for weight loss?
Yes, Mounjaro (tripeptide) has helped with weight loss in adults with obesity in a 72-week clinical trial.
Is tripeptide harmful to the kidneys?
The results show that tripeptide participants experienced fewer renal complications than insulin recipients. In particular, the rates of new onset of macroalbuminuria, a signal of poor renal outcomes, were significantly lower in the tripeptide arm.
Who should not take tirzepatide?
Given the theoretical risk, tripeptide should be avoided in those with a personal or family history of medullary thyroid carcinoma. Patients with a history of MEN 2 (multiple endocrine neoplasia syndrome type-2) should also avoid tripeptide.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.